Physician profile
Robert A Poling
NPI 1205888575
$5,580.13
in general payments reported to CMS, 2019-2025
36 companies · $643 in 2025
The $643 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $731 · 2021: $644 · 2022: $728 · 2023: $954 · 2024: $1,041 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $492.05 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Janssen Pharmaceuticals, INC | $452.68 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $445.71 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $444.22 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $426.24 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $422.24 | 2019-2025 | |
| Boston Scientific Corporation | $373.31 | 2023-2024 | Watchman Flx |
| Lilly USA, LLC | $290.98 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $288.22 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.27 | 2020-2023 | Synjardy, Jardiance, Tradjenta |
| Kowa Pharmaceuticals America, INC. | $219.06 | 2019-2024 | Livalo, Seglentis, Zoryve |
| Radius Health, INC. | $214.68 | 2022-2025 | Tymlos |
| Exact Sciences Corporation | $200.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $176.59 | 2019-2025 | Cuvitru, Gattex |
| Amarin Pharma, INC. | $135.75 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $126.90 | 2019-2023 | |
| Ibsa Pharma INC. | $83.99 | 2021-2025 | Tirosint, Licart, Flector |
| Axsome Therapeutics, INC. | $50.24 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $45.36 | 2022 | |
| Abbvie INC. | $44.75 | 2021-2022 | |
| Therapeuticsmd, INC. | $44.37 | 2019 | |
| Abiomed | $39.25 | 2024 | Impella |
| Almatica Pharma LLC | $37.23 | 2023 | Loreev Xr, Gralise |
| Inspire Medical Systems, INC. | $33.63 | 2025 | Inspire |
| Kaleo, INC. | $33.21 | 2022 | |
| Astellas Pharma US INC | $31.95 | 2019 | |
| Phathom Pharmaceuticals, INC. | $23.63 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.54 | 2022 | |
| Cardiovascular Systems INC. | $22.16 | 2022 | |
| Corcept Therapeutics | $20.46 | 2025 | Korlym |
| Allergan, INC. | $18.56 | 2020 | |
| Currax Pharmaceuticals LLC | $17.61 | 2025 | Contrave |
| Biohaven Pharmaceuticals, INC. | $16.71 | 2021 | |
| Shire North American Group INC | $16.29 | 2019 | |
| Esperion Therapeutics, INC. | $15.26 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.79 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Poling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.